Cancer patients are at an increased risk for developing ONJ due to certain cancer treatments. Specifically, therapies such as bisphosphonates and denosumab, which are used to manage bone metastases and hypercalcemia, have been linked to the development of ONJ. These drugs work by inhibiting bone resorption, which can inadvertently affect the jaw bone's ability to repair and regenerate.
